论文部分内容阅读
目的评价来氟米特治疗狼疮性肾炎(lupus nephritis,LN)的疗效和安全性。方法检索Cochrane图书馆,PubMed,EMBASE,中国生物医学文献光盘数据库、中国期刊全文数据库和中国维普数据库等中关于来氟米特治疗LN疗效和安全性的随机对照试验(randomized controlled trial,RCT)文献。检索时间均从建库至2010年5月30日,由3名系统评价员进行文献资料提取和质量评价。疗效判断分为完全缓解(CR)、部分缓解(PR)和治疗无效(NR)。采用RevMan4.2软件进行Meta分析。结果共检索到62篇文献,符合纳入标准的3篇RCT文献(n=117)进入Meta分析。Meta分析结果显示:OR=0.36(95%CI,0.14～0.90)>0,菱形完全位于垂直线的左侧。结论来氟米特与环磷酰胺相比,在保证疗效的同时有更好的耐受性和安全性。
Objective To evaluate the efficacy and safety of leflunomide in the treatment of lupus nephritis (LN). Methods Randomized controlled trial (RCT) of the Cochrane Library, PubMed, EMBASE, Chinese Biomedical Literature CD-ROM, Chinese Journal Full-text Database and Chinese VIP database were searched for the efficacy and safety of leflunomide in the treatment of LN. . Retrieval time from the construction of the library to May 30, 2010, by the three system evaluators for document extraction and quality evaluation. Efficacy judgments were divided into complete remission (CR), partial remission (PR) and treatment ineffective (NR). RevMan4.2 software for Meta analysis. Results A total of 62 articles were retrieved and 3 RCT documents (n = 117) were included in the meta-analysis. Meta-analysis showed that OR = 0.36 (95% CI, 0.14-0.90)> 0 and the rhombus was completely located on the left side of the vertical line. Conclusion Leflunomide compared with cyclophosphamide, while ensuring the efficacy of better tolerance and safety.